Vestal Point Capital LP Buys Shares of 83,333 Tenax Therapeutics, Inc. (NASDAQ:TENX)

Vestal Point Capital LP purchased a new position in shares of Tenax Therapeutics, Inc. (NASDAQ:TENX) in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 83,333 shares of the specialty pharmaceutical company’s stock, valued at approximately $288,000.

Separately, Stonepine Capital Management LLC purchased a new position in Tenax Therapeutics during the 3rd quarter worth $173,000. Institutional investors and hedge funds own 1.67% of the company’s stock.

Tenax Therapeutics Stock Performance

TENX opened at $5.33 on Friday. Tenax Therapeutics, Inc. has a 1-year low of $2.77 and a 1-year high of $31.20. The stock’s 50 day simple moving average is $4.19 and its 200 day simple moving average is $3.77.

Analyst Upgrades and Downgrades

TENX has been the topic of several analyst reports. Leerink Partnrs raised shares of Tenax Therapeutics to a “strong-buy” rating in a report on Thursday, October 24th. StockNews.com initiated coverage on Tenax Therapeutics in a research report on Thursday, September 26th. They set a “sell” rating on the stock. Leerink Partners began coverage on Tenax Therapeutics in a research note on Thursday, October 24th. They issued an “outperform” rating and a $16.00 price target on the stock. Guggenheim assumed coverage on Tenax Therapeutics in a research report on Monday, October 14th. They issued a “buy” rating and a $16.00 price objective for the company. Finally, William Blair began coverage on shares of Tenax Therapeutics in a research report on Monday, September 30th. They set an “outperform” rating on the stock. One research analyst has rated the stock with a sell rating, four have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $16.00.

Tenax Therapeutics Profile

Tenax Therapeutics, Inc develops and commercializes pharmaceutical products containing imatinib for the treatment of pulmonary arterial hypertension in the United States. The company develops TNX-101 (IV), TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia.